ArticleJournal of animal science and biotechnology2026
Rosemary-derived triterpene acids improve growth and lipid metabolism in juvenile grass carp (Ctenopharyngodon idella) through the gut-liver axis by tissue-specifically regulating the farnesoid X receptor.
Article in Journal of animal science and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRosemary-derived triterpene acids (TAs), primarily composed of ursolic acid, oleanolic acid, and betulinic acid, exhibit multiple bioactive properties. However, their effects on lipid metabolism and the underlying regulatory pathways remain unclear. This study investigated the effects of dietary supplementation with TAs on the growth performance, digestive and absorptive function, and hepatic lipid metabolism in juvenile grass carp (Ctenopharyngodon idella).
methodsIn this trial, 2,160 juvenile grass carp (average weight 13.04 ± 0.02 g) were randomly allocated to six dietary treatments, each comprising six replicates with 60 fish per replicate. Fish were fed diets supplemented with increasing concentrations of TAs (0, 58.80, 179.30, 261.90, 312.00, and 390.00 mg/kg) for 70 d. At the end of the trial, relevant samples were collected for subsequent analyses.
resultsThe results demonstrated that dietary supplementation with TAs significantly increased specific growth rate (SGR), whole-body crude protein (CP) levels, and protein retention value (PRV) in juvenile grass carp, while reducing whole-body ether extract (EE) levels. Moreover, dietary supplementation with TAs significantly enhanced the activities of intestinal digestive enzymes and brush-border enzymes, thereby improving the digestive and absorptive capacity of juvenile grass carp. In the liver, dietary supplementation with TAs markedly inhibited lipid synthesis while promoting lipid utilization. The effects of TAs on lipid metabolism were associated with activation of the hepatic farnesoid X receptor (FXR) pathway, involving peroxisome proliferator-activated receptor alpha (PPARα) and sterol regulatory element-binding protein 1 (SREBP-1). Furthermore, TAs modulated the gut-liver axis by inhibiting the intestinal FXR-sphingomyelin phosphodiesterase 3 (SMPD3)-ceramide pathway, which may contribute to reduced hepatic lipid deposition. Quadratic regression analysis showed that the optimal dietary TAs supplementation levels were 245.00 mg/kg (SGR), 218.33 mg/kg (intestinal lipase activity), and 267.64 mg/kg (hepatic hormone-sensitive lipase activity).
conclusionsThe addition of TAs to the diet improved growth performance, digestive and absorptive capacity, and liver lipid utilization in juvenile grass carp. This work reveals the potential application of TAs in aquaculture and provides a theoretical basis for the development of functional feed additives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.